CVS forecast an adjusted profit of $1.14- $1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to the company rose 13.4 percent to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31, helped by strong demand in its pharmacy business.» Read More
Shares of Valeant are down 6 percent after buying Sprout Pharmaceuticals, the maker of the "female Viagra" drug. CNBC's Meg Tirrell discusses drug deals.
Valeant to purchase flibanserin-maker Sprout for $1 billion.
The FDA approved the first prescription drug for enhancing female libido.
Wal-Mart Stores Inc said on Tuesday that lower margins in its pharmacy business had emerged as a drag on profits, as it gets paid less by drug plan managers and as fewer customers pay in cash, since Obamacare has increased the ranks of insured Americans. The company warned that the margin squeeze would continue for at least the remainder of the year, although a...
Aug 18- Wal-Mart Stores Inc reported weaker quarterly earnings and lowered its annual forecast on Tuesday, as it copes with higher labor costs, a squeeze on pharmacy margins and sliding sales at its British supermarket chain. Net profit attributable to Wal-Mart fell to $3.48 billion, or $1.08 per share, in the second quarter ended July 31, from $3.92 billion, or...
Aug 18- Wal-Mart Stores Inc reported weaker-than-expected quarterly earnings and lowered its annual forecast on Tuesday, citing higher costs from adding worker hours as well as weaker margins in its U.S. pharmacy business. Wal-Mart lowered its forecast for the year ending in January to a range of $4.40 to $4.70 from its outlook of $4.70 to $5.05 in February.
Aug 18- Wal-Mart Stores Inc reported weaker-than-expected quarterly earnings and lowered its full-year forecast, citing higher costs from adding worker hours as well as weaker margins in its U.S. pharmacy business. For the year ending in January, Wal-Mart lowered its earnings-per-share forecast to a range of $4.40 to $4.70 from its outlook of $4.70 to $5.05...
Aug 18- Wal-Mart Stores Inc reported weaker-than-expected quarterly earnings and lowered its full-year forecast on Tuesday, citing investments in staffing and weaker margins in its U.S. pharmacy business. Net profit attributable to Wal-Mart fell to $1.08 per share, in the second quarter ended July 31 from $1.21 per share, a year earlier.
Don Weatherhold, Aprecia Pharmaceuticals CEO, discusses Aprecia and the technology of 3-D printing and prescription drugs.
The drugstore is expanding to accept Apple Pay and Google Wallet Saturday after slashing support last year. Re/code reports.
Rite Aid to start accepting mobile payments this Saturday.
CVS says Pfizer's Viagra will no longer be an approved formula in 2016, reports CNBC's Bertha Coombs.
Chinese police are investigating if two distillers added impotence treatment drug Viagra to their liquor in the latest food-safety scare in China.
Amid rising health care and drug costs, a group of doctors at the Mayo Clinic is trying to lower the costs of cancer treatments for patients. Insight, with Dr. Ayalew Tefferi, Mayo Clinic.
Lindsey Bell, Senior Analyst at S&P Capital IQ, explains why she's expecting a monthly increase of 0.3 percent.
New Yorkers suffering from cancer, epilepsy, Crohn's disease and Parkinson's disease may soon be able to access medical marijuana in the state. Jason Cranford, expert botanist and Director of Cultivation at the Compassionate Care Center of New York, provides insight.
How Alzheimer's drug Solanezumab works to help treat the underlying cause of the disease, with CNBC's Meg Tirrell.
Costco has been subpoenaed by the federal government concerning prescriptions for controlled substances.
CNBC's Meg Tirrell provides insight to what Foundation Medicine, a cancer testing company, can do to better inform doctors on cancer via a database filled with research.
A new plan for Express Scripts regarding cancer drugs, with CNBC's Meg Tirrell.